Delivery Order SPE2DR25D2104-SPE2DR26F3PGZ
- Not listed
- AmerisourceBergen Drug Corp was awarded a delivery order by the Defense Logistics Agency (DLA) on November 18, 2025, with a ceiling value of $1,620.01 for 90-count tablets of Verquvo 10 mg. The contract is structured as a firm fixed-price delivery order with an ultimate completion date of November 19, 2025, and will be performed at the contractor's facility in Conshohocken, Pennsylvania. This award was not set-aside and was competitively awarded, demonstrating AmerisourceBergen's capability to...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 25, 2025, for the supply of Verquvo 5 mg tablets (14-count units) with a ceiling value of $7,605.92 under a firm fixed price contract. This is a non-set-aside, competitively awarded delivery order with an ultimate completion date of September 26, 2025. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor and critical vendor for federal medical...
- The Defense Logistics Agency awarded a $1,243.00 delivery order to AmerisourceBergen Drug Corp for VERQUVO 10 mg tablets (30-count units) on April 22, 2025, with completion scheduled for April 23, 2025. This firm fixed-price, non-set-aside contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 through December 2026. The pharmaceutical products will be delivered to AmerisourceBergen's...
- The Defense Logistics Agency awarded a $2,886.90 delivery order to AmerisourceBergen Drug Corp on August 15, 2025, for the supply of Verquvo 2.5 mg tablets (30-count units). This firm fixed price, non-set-aside contract is expected to be completed by August 18, 2025, with performance taking place at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. The delivery order falls under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical,...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $8,669.85 to AmerisourceBergen Drug Corp for the supply of Verquvo 10 mg tablets (30-count packaging) on June 13, 2025, with completion scheduled for June 16, 2025. This competitively awarded, firm fixed price delivery order carries no set-aside designation and will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and...
- The Defense Logistics Agency awarded a delivery order valued at $2,415.96 to AmerisourceBergen Drug Corp for Verquvo 5 mg tablets (14-count packaging) on September 12, 2025, with completion scheduled for September 15, 2025. This firm fixed-price delivery order is unclassified and carries no set-aside designation, indicating competitive award status. The award leverages AmerisourceBergen's position as a major pharmaceutical distributor and represents a child order under the company's larger...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for VERQUVO 10 mg tablets (30-count units) valued at $2,749.50 under a firm fixed-price contract type. The award was made on June 16, 2025, with an ultimate completion date of June 17, 2025. This delivery order is not set-aside and was competitively awarded to the Conshohocken, Pennsylvania-based pharmaceutical distributor. AmerisourceBergen Drug Corp serves as a critical vendor within the federal medical...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,761.08 to AmerisourceBergen Drug Corp for the supply of Verquvo 2.5 mg tablets (30-count packaging) on August 26, 2025, with an ultimate completion date of August 27, 2025. This firm fixed-price delivery order was competitively awarded without set-aside restrictions and will be performed at AmerisourceBergen's Conshohocken, Pennsylvania facility. The award represents a child contract under AmerisourceBergen's larger...
- This is a federal contract award from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $1,039.56 firm fixed-price delivery order is for the supply of VERQUVO 10 MG TABLET 30S, a prescription medication. The contract has an ultimate completion date of February 13, 2025. AmerisourceBergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves...
- The Defense Logistics Agency awarded a delivery order valued at $2,310.12 to AmerisourceBergen Drug Corp for VERQUVO 5 mg tablets (100-unit dose packages) with a completion date of September 2, 2025. This is a firm fixed price delivery order with no set-aside designation, competitively awarded to the prime contractor. The pharmaceutical product will be delivered to AmerisourceBergen's facility in Conshohocken, Pennsylvania, which serves as the company's corporate headquarters and a key...
- SPE2DR25D2104Indefinite Delivery Contract
- SPE2DR25D2104-SPE2DR26F3PGZDelivery Order
The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for $4,992.61 on November 18, 2025, for the supply of Verquvo 10 mg tablets (90-count supply). This is a firm fixed-price delivery order with no set-aside designation, awarded through competitive procurement. The contract is scheduled for ultimate completion on November 19, 2025, with performance based at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The IDC serves as a comprehensive pharmaceutical support vehicle enabling AmerisourceBergen to supply medications, vaccines, medical devices, and related healthcare commodities to support military and federal healthcare systems globally. As a major pharmaceutical distributor and critical federal medical vendor, AmerisourceBergen maintains an extensive portfolio of federal contract awards for pharmaceuticals across multiple therapeutic domains, demonstrating capability to meet complex federal procurement requirements through open competition.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $5.0k | 11/18/25 |